ELAN vs IDXX vs TMO Stock Comparison

Elanco Animal Health, Idexx Laboratories and Thermo Fisher Scientific Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

11 decided of 12

Idexx Laboratories leads on 5 of the 12 questions below (Idexx Laboratories 5, Thermo Fisher Scientific 3, Elanco Animal Health 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANIDXXTMOLeader
Larger companyMarket capitalisation $13.25B $55.34B $255.60B TMO
Cheaper on earningsLower P/E, profitable companies only -90.2x 46.8x 36.1x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 44.6x 27.0x ELAN
Faster revenue growthRevenue growth, trailing twelve months +12.1% +11.9% +8.3% ELAN
More profitableNet margin, trailing twelve months -2.9% 25.4% 14.9% IDXX
Better return on capitalReturn on invested capital 6.9% 45.4% 8.0% IDXX
Less leveragedLower net debt / EBITDA 2.3x 0.4x 3.1x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +21.8% +0.4% +20.7% ELAN
Better 5-year returnAnnualised price return, 5 years -4.1%/yr +2.3%/yr +2.0%/yr IDXX
Less volatileAnnualised volatility, 1 year 43.4% 36.2% 30.7% TMO
Higher overall scoreMean of the five percentile scores vs peers 69/100 76/100 60/100 IDXX

Percentile Scorecard

ELANIDXXTMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANIDXXTMO
Valuation 92 #52 of 660 74 #175 of 660 62 #94 of 243
Growth 67 #208 of 619 70 #184 of 619 41 #136 of 228
Profitability 85 #90 of 595 98 #12 of 595 82 #40 of 222
Financial Health 31 #473 of 683 46 #371 of 683 31 #172 of 248
Shareholder Returns 73 #126 of 459 94 #30 of 459 82 #29 of 158
Overall 69 76 60
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • TMO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANIDXXTMOSPY
1 month +18.8%+33.1%+4.0% -2.0%
3 months +13.2%+27.8%+19.1% -2.8%
6 months +34.9%+33.2%+59.7% +2.0%
Year to date +18.4%+4.1%+20.8% +10.6%
1 year +21.8%+0.4%+20.7% +12.2%
3 years +136.2%+55.0%+52.5% +68.1%
3 years, per year +33.2%+15.7%+15.1% +18.9%
5 years -18.9%+12.1%+10.2% +61.4%
5 years, per year -4.1%+2.3%+2.0% +10.1%
10 years —+545.1%+362.9% +248.5%
10 years, per year —+20.5%+16.6% +13.3%

Risk

MeasureELANIDXXTMOSPY
Volatility, 1Y 43.4%36.2%30.7% 13.6%
Downside volatility, 1Y 43.7%32.6%29.2% 13.9%
Beta vs S&P 500, 1Y 1.320.840.71 1.00
Return / volatility, 1Y 0.500.010.67 0.90
Max drawdown, 5Y -75.0%-50.9%-41.5% -25.4%
From 52-week high -0.2%-8.1%-3.0% -3.2%
52-week high $26.84$766.68$721.63 $779.14
52-week low $19.80$504.70$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANIDXXTMO
P/E now vs peer median -91.1xmedian 17.0x 47.0xmedian 17.0x 36.6xmedian 26.5x
P/S now vs peer median 2.6xmedian 8.4x 11.9xmedian 8.4x 5.5xmedian 2.7x
EV/EBITDA now vs peer median 11.8xmedian 14.6x 33.7xmedian 14.6x 25.5xmedian 18.4x
P/FCF now vs peer median 32.8xmedian 19.0x 42.6xmedian 19.0x 34.2xmedian 25.4x
P/B now vs peer median 2.0xmedian 2.0x 29.7xmedian 2.0x 4.7xmedian 2.5x
PEG now vs peer median -1.82median 0.43 3.10median 0.43 4.84median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANIDXXTMO
Revenue $5.15B $4.66B $47.35B
Gross profit $2.89B $2.92B $19.45B
Operating income $720.00M $1.51B $8.47B
Net income -$147.00M $1.18B $7.09B
Free cash flow $408.00M $1.30B $7.60B
R&D $381.00M $266.87M $1.40B
EPS (diluted) $-0.29 $14.96 $19.06
Cash & equivalents $465.00M $197.54M $5.46B
Total debt $3.71B $848.88M $41.37B
Shares (diluted) 506.50M 79.05M 371.00M
Enterprise value $11.29B $54.56B $232.12B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANIDXXTMO
P/E -91.1x 47.0x 36.6x
P/FCF 32.8x 42.6x 34.2x
P/Operating cash flow 21.8x 39.1x 27.8x
P/S 2.6x 11.9x 5.5x
P/B 2.0x 29.7x 4.7x
P/Tangible book 3.7x 31.7x 7.1x
EV/EBITDA 11.8x 33.7x 25.5x
EV/EBIT 23.1x 37.3x 34.8x
EV/Revenue 3.2x 12.0x 6.2x
EV/FCF 40.8x 43.1x 38.8x
EV/Operating cash flow 27.1x 39.6x 31.6x
PEG (3Y EPS CAGR) -1.82 3.10 4.84

Growth

14 metrics
MetricELANIDXXTMO
Revenue growth (1Y) 12.1% 11.9% 8.3%
Revenue CAGR (3Y) 5.6% 9.1% 2.9%
Gross profit growth (1Y) 14.6% 13.7% 7.8%
Gross profit CAGR (3Y) 4.9% 10.8% 4.0%
Operating income growth (1Y) 20.6% 15.3% 12.8%
Operating income CAGR (3Y) 41.2% 11.8% 7.2%
Net income growth (1Y) -508.3% 15.1% 7.9%
Net income CAGR (3Y) 49.5% 12.8% 6.2%
EPS growth (1Y) -500.5% 17.4% 9.7%
EPS CAGR (3Y) 50.0% 15.1% 7.6%
Operating cash flow growth (1Y) -2.4% 30.4% 21.9%
Operating cash flow CAGR (3Y) 69.1% 19.6% 4.5%
Free cash flow growth (1Y) 10.9% 35.3% 24.3%
Free cash flow CAGR (3Y) 117.8% 24.2% 5.1%

Profitability

14 metrics
MetricELANIDXXTMO
Gross margin 56.2% 62.7% 41.1%
EBITDA margin 27.5% 35.7% 24.4%
Operating margin 14.0% 32.3% 17.9%
Pretax margin -1.8% 31.7% 16.7%
Net margin -2.9% 25.4% 14.9%
FCF margin 7.9% 28.0% 16.0%
Operating cash flow margin 11.9% 30.4% 19.7%
Return on equity -2.2% 67.9% 13.2%
Return on assets -1.1% 33.1% 6.2%
Return on invested capital 6.9% 45.4% 8.0%
Return on capital employed 6.2% 65.2% 8.5%
Asset turnover 0.4x 1.3x 0.4x
Cash conversion (OCF / net income) -4.2x 1.2x 1.3x
Stock comp / revenue 1.5% 1.4% 0.7%

Financial Health

11 metrics
MetricELANIDXXTMO
Debt / assets 27.8% 22.9% 36.2%
Debt / equity 0.6x 0.5x 0.8x
Net debt / EBITDA 2.3x 0.4x 3.1x
Debt / FCF 9.1x 0.7x 5.4x
Liabilities / assets 50.3% 49.6% 52.1%
Equity / assets 49.7% 50.4% 47.9%
Interest coverage 2.8x 43.5x 12.0x
Current ratio 2.1x 1.2x 1.8x
Quick ratio 0.9x 0.7x 1.2x
Cash ratio 0.3x 0.2x 0.4x
Altman Z-score 1.72 23.56 4.18

Shareholder Returns

7 metrics
MetricELANIDXXTMO
Dividend yield – – 0.3%
Net buyback yield -0.3% 1.7% 1.6%
Shareholder yield -0.3% 1.7% 1.8%
Payout ratio (earnings) – – 9.5%
Payout ratio (FCF) – – 8.9%
Dividend growth (1Y) – – 8.0%
Dividend CAGR (3Y) – – 10.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANIDXXTMO
Forward P/E 23.7xFY2026 44.6xFY2026 27.0xFY2026
EPS, next fiscal year $1.13FY2026 $15.78FY2026 $25.92FY2026
EPS growth, next FY +20.2%FY2026 +20.6%FY2026 +13.3%FY2026
EPS growth, the year after +22.1% +12.3% +2.2%
Revenue, next fiscal year $4.82BFY2026 $5.03BFY2026 $50.12BFY2026
Revenue growth, next FY +2.4%FY2026 +17.0%FY2026 +12.5%FY2026
Revenue growth, the year after +19.4% +0.4% -2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANIDXXTMO
Held by institutions 100.0% 93.6% 90.2%
Institutions holding 526 1,292 2,627
Change in shares held, QoQ +4.4% +4.1% +0.8%
Institutions buying 246 590 1,145
Institutions selling 211 496 1,145
Buyers to sellers 1.17 1.19 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANIDXXTMO
ELAN 1.00 0.42 0.27
IDXX 0.42 1.00 0.29
TMO 0.27 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, IDXX and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Idexx Laboratories (IDXX) $55.34B, Thermo Fisher Scientific (TMO) $255.60B.

Which stock is cheaper, ELAN, IDXX and TMO?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Elanco Animal Health (ELAN) -90.2x, Idexx Laboratories (IDXX) 46.8x, Thermo Fisher Scientific (TMO) 36.1x). On next year's consensus earnings, Elanco Animal Health (ELAN) is cheapest (Elanco Animal Health (ELAN) 23.7x, Idexx Laboratories (IDXX) 44.6x, Thermo Fisher Scientific (TMO) 27.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elanco Animal Health (ELAN) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Idexx Laboratories (IDXX) +11.9%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Idexx Laboratories (IDXX) 25.4%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Idexx Laboratories (IDXX) leads (Elanco Animal Health (ELAN) 6.9%, Idexx Laboratories (IDXX) 45.4%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Elanco Animal Health (ELAN) returned the most: Elanco Animal Health (ELAN) +21.8%, Idexx Laboratories (IDXX) +0.4%, Thermo Fisher Scientific (TMO) +20.7%. Over five years, Idexx Laboratories (IDXX) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Idexx Laboratories (IDXX) +2.3%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Elanco Animal Health (ELAN) 0.00%, Idexx Laboratories (IDXX) 0.00%, Thermo Fisher Scientific (TMO) 0.00%. Elanco Animal Health (ELAN) and Idexx Laboratories (IDXX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Idexx Laboratories (IDXX) 36.2%, Thermo Fisher Scientific (TMO) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, IDXX and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.